JPMorgan downgrades Clorox stock rating on cost pressures

JPMorgan downgraded Clorox to Underweight from Neutral and cut its price target to $99 from $117, implying downside from the current $102.38 share price. The firm cited weaker category growth, high private-label exposure in trash bags and surface cleaning, and cost pressure from diesel and resins, while expecting downside risk to estimates and a narrower guidance range ahead of F3Q26 results on April 30. Clorox recently posted mixed Q2 2026 results, with EPS of $1.39 missing the $1.44 consensus despite revenue of $1.67 billion topping estimates.

Analysis

The market is starting to reprice CLX not as a resilient staple compounder but as a margin-sensitive, low-growth defensive with limited pricing power. The important second-order effect is that private label pressure and weak low-income demand tend to persist longer than headline consumer sentiment, so this is less a one-quarter earnings miss story and more a multi-quarter share and mix problem. If management narrows guidance, it will likely validate that the earnings setup into the print is asymmetric to the downside because fixed cost leverage works both ways when category growth stalls.

There is also a cleaner beneficiary set than CLX itself: discounters and private-label retailers can absorb share without paying up for promotion, while branded peers with more premium mix and less exposure to trash bags/surface cleaning should hold up better. Higher diesel and resin sensitivity is particularly painful in a weak demand environment because it compresses gross margin twice—first through input cost, then through the inability to pass through. That makes any short-term cost relief from commodities less helpful unless volume re-accelerates, which is unlikely before the back half of the year.

The contrarian angle is that the stock already trades near the lower end of its range, so the easy short has likely passed; the real issue is whether consensus still assumes a normalization that can’t happen without a healthier consumer. If the GOJO integration delivers enough mix support, the market may eventually give CLX credit for portfolio breadth, but that is a 2-4 quarter story, not a near-term catalyst. For now, the setup favors selling rallies into the print rather than chasing downside after the downgrade.

COTY is a relative bystander here, but it can still benefit from any broad staple de-rating if investors rotate out of defensive consumer names and into lower-quality cyclicality where expectations are already reset. The broader tape implication is that consumer demand softness is now a valuation problem, not just an earnings problem, and that usually spills into other household-product names with high private-label exposure.

Key Decisions for Investors

• Short CLX into the April 30 F3Q26 print or sell post-rally strength; target 1-2 quarters of downside if guidance narrows and margins disappoint, with risk managed above the recent range high.
• Use a bearish put spread on CLX for the next 4-8 weeks; risk/reward is best if implied volatility stays contained and the stock reverts toward the low-$90s.
• Pair trade: long a stronger premium-staples name vs short CLX over the next 1-2 quarters to isolate private-label and cost-pressure risk from broader consumer defensiveness.
• Avoid adding to long CLX until the market sees evidence of volume stabilization or cleaner input-cost relief; the contrarian long case only works on a 2-4 quarter horizon, not into the print.
• If holding COTY, use it as a relative long only on evidence that consumer discretionary weakness is becoming selective rather than broad-based; otherwise keep exposure small because the macro tape is not rewarding consumer beta.